Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05462795 · ClinicalTrials.gov registry record
Liquid Biopsy for Early Non-small Lung Cancer Detection
A clinical trial, sponsored by University of Arizona.
- Completed
- Registry status
- 171
- Enrollment target
NCT05462795 is a clinical trial that has completed, run by University of Arizona. The registered enrollment target is 171 participants.
The verdict
NCT05462795 has completed, sponsored by University of Arizona.
- COMPLETED
- Registry status
- 171 participants
- Enrollment target
Study Summary
This clinical trial will assess the performance of a liquid biopsy assay to identify cancer in indeterminant pulmonary nodules identified by CT screening of high-risk individuals and evaluate the capability of the liquid biopsy assay to monitor response to surgical resection.
Interventions
- DIAGNOSTIC_TEST Liquid biopsy for aberrant DNA methylation analysis - Indeterminate pulmonary nodule
- DIAGNOSTIC_TEST Liquid biopsy for aberrant DNA methylation analysis - Known lung cancer for surgical resection
- DIAGNOSTIC_TEST Liquid biopsy for aberrant DNA methylation analysis - Healthy volunteer
- DIAGNOSTIC_TEST Liquid biopsy for aberrant DNA methylation analysis - Benign lung disease
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 171 participants |
| Start Date | 2022-08-02 |
| Est. Completion | 2024-03-22 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05462795
The ClinicalTrials.gov registry entry for NCT05462795 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 171 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Arizona, which has 349 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Liquid biopsy for aberrant DNA methylation analysis - Indeterminate pulmonary nodule is the first listed.
NCT05462795 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05462795 about?
NCT05462795 is a clinical study titled "Liquid Biopsy for Early Non-small Lung Cancer Detection". This clinical trial will assess the performance of a liquid biopsy assay to identify cancer in indeterminant pulmonary nodules identified by CT screening of high-risk individuals and evaluate the capability of the liquid biopsy assay to monitor response to surgical resection.
What is the current status of trial NCT05462795?
This trial is currently completed. The enrollment target is 171 participants. The study started on 2022-08-02. Estimated completion is 2024-03-22.
What interventions are being tested in trial NCT05462795?
The interventions under investigation include: Liquid biopsy for aberrant DNA methylation analysis - Indeterminate pulmonary nodule (DIAGNOSTIC_TEST), Liquid biopsy for aberrant DNA methylation analysis - Known lung cancer for surgical resection (DIAGNOSTIC_TEST), Liquid biopsy for aberrant DNA methylation analysis - Healthy volunteer (DIAGNOSTIC_TEST), Liquid biopsy for aberrant DNA methylation analysis - Benign lung disease (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05462795?
This trial is sponsored by University of Arizona, which has 349 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.